Drug Profile


Alternative Names: CB24; Cytotoxic PLA2; NSC-624244

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Ventech
  • Developer Celtic Biotech; Celtic Biotech Iowa
  • Class Antineoplastics; Venoms
  • Mechanism of Action Apoptosis stimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Cancer

Most Recent Events

  • 10 Mar 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in France (IV)
  • 13 Feb 2015 Celtic Biotech suspends enrolment in a phase I trial in Cancer in France (NCT01481532)
  • 16 Jan 2015 Phase I development is ongoing France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top